Launches

Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains

  • by

Shots: Qiagen’s QIAseq SARS-CoV-2 primer panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to track changes in the viral genome The two-step process uses advanced QIAseq technologies to conduct reverse transcription and cDNA synthesis from a viral RNA sample,… Read More »Qiagen Launches QIAseq SARS-CoV-2 Primer Panel for Tracking COVID-19 Mutations and Strains

Samsung Bioepis Launches Ontruzant (trastuzumab, biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

  • by

Shots: The company launches its first oncology treatment Ontruzant (trastuzumab), a biosimilar referencing Herceptin in Brazil. The biosimilar has received ANVISA’s approval for the treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer Ontruzant is being supplied to SUS through a PDP… Read More »Samsung Bioepis Launches Ontruzant (trastuzumab, biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19 in India

  • by

Shots: Mylan launches Desrem (remdesivir) addressing the unmet needs amid COVID-19. The drug is approved for the treatment of suspected or laboratory-confirmed incidences of COVID-19 in adults and children hospitalized with severe symptoms Mylan will manufacture Desrem in its state-of-the-art injectable facility in Bangalore, India,… Read More »Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19 in India